Wall Street Analysts Believe Editas (EDIT) Could Rally 139%: Here's is How to TradeZacks Investment Research • 10/31/22
Editas Medicine to Host Conference Call Discussing Third Quarter 2022 Results and Corporate UpdateGlobeNewsWire • 10/26/22
Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the European Society of Gene and Cell Therapy Annual MeetingGlobeNewsWire • 10/13/22
Editas Medicine, Inc. (EDIT) Management Presents at Morgan Stanley 20th Annual Global Healthcare Conference Call TranscriptSeeking Alpha • 09/12/22
Editas Medicine, Inc. (EDIT) Presents at 2022 Wells Fargo Healthcare Conference (Transcript)Seeking Alpha • 09/07/22
Editas (EDIT) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?Zacks Investment Research • 08/19/22
Does Editas (EDIT) Have the Potential to Rally 65% as Wall Street Analysts Expect?Zacks Investment Research • 08/16/22
Editas Medicine, Inc. (EDIT) CEO Gilmore O'Neill on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/04/22
Editas Medicine Announces Clinical Achievements in the Development of EDIT-301 for Sickle Cell DiseaseGlobeNewsWire • 07/27/22
Editas Medicine to Host Conference Call Discussing Second Quarter 2022 Results and Corporate UpdatesGlobeNewsWire • 07/26/22